Locations:
SearchA study of 355 patients identifies risk factors for increased mortality in day +100 survivors after allogeneic hematopoietic stem cell transplantation. The study, led by senior author Betty Hamilton, MD, Associate Director of Cleveland Clinic Cancer Center’s Blood and Marrow Transplant Program, found that particular disease- and transplant-related and social factors predicted survival after 100 days.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
“Identifying factors that can increase mortality allows us to risk-stratify patients for more careful follow-up and support,” says Dr. Hamilton. “The next step is to focus efforts on improving outcomes for these more vulnerable patients.”
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients